Psyllium Husk vs Retatrutide for appetite
Short answer: For appetite, more users report improvement with Psyllium Husk — 100% of 8 reports, versus 73% of 84 for Retatrutide.
Psyllium Husk has 49 meta-analyses and 145 randomized trials on PubMed; Retatrutide has 22 and 6.
Based on 114 reports about Psyllium Husk and 446 about Retatrutide. Not medical advice.
| Psyllium Husk Supplement | Retatrutide Peptide | |
|---|---|---|
| User score | 70 | 71 |
| Verdict | Mostly positive | Mostly positive |
| Positive of reports that state an outcome | 79% | 76% |
| Reports | 114 | 446 |
| Research | AResearch: Strong | BResearch: Moderate |
| Meta-analyses / RCTs | 49 / 145 | 22 / 6 |
| Mainly used for | ||
| Weight loss % reporting improvement | 100% (3) | 91% (222) |
| Appetite % reporting improvement | 100% (8) | 73% (84) |
| Focus % reporting improvement | 100% (2) | 83% (6) |
| Energy % reporting improvement | 100% (3) | 69% (75) |
| Sleep % reporting improvement | 100% (3) | 31% (26) |
| Anxiety % reporting improvement | — | 40% (5) |
| Mood % reporting improvement | — | 66% (32) |
| Performance % reporting improvement | — | 82% (33) |
| Recovery % reporting improvement | — | 100% (8) |
| Pain & inflammation % reporting improvement | — | 78% (9) |
| Digestion % reporting improvement | 88% (68) | 46% (13) |
| Libido % reporting improvement | — | 25% (12) |
| Hormones % reporting improvement | — | 100% (13) |
| Blood sugar % reporting improvement | — | 75% (4) |
| Heart & lipids % reporting improvement | 100% (13) | 37% (19) |
| Common side effects | stomach issues, dizziness, gagging/nausea from, blockage risk | nausea, fatigue, stomach issues, insomnia |
| Typical dose reported | rotated | Not listed |
Several foods distinctly modify LDL cholesterol levels. The results may aid future guidelines and dietary advice for hypercholesterolemia.
Nutr Metab Cardiovasc Dis, 2021 ↗“It helped me heal my intestinal issues. I felt amazing after about a week and my mental clarity and energy skyrocketed.”
This systematic review identifies the state and mechanism of action of emerging pharmacotherapies undergoing or having completed phase 2 and phase 3 clinical trials. The information provided herein furthers the understanding of obesity management, implying direct clinical implications and stimulating research initiatives.
Pharmacol Rev, 2025 ↗“Drastically reduced appetite: At 5mg, I experienced near-total suppression of hunger and cravings. Steady, effortless fat loss: I didn't have to track macros obsessively or do extreme cardio.”
Related comparisons
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate